Professor Michael Geoffrey Lewis

Michael Geoffrey Lewis

Institute of Immunology and Immunotherapy
Professor Life Science Innovation

Contact details

Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Birmingham alumni Mike has 30 years global Health industry experience and among other roles is currently Chair of 5 Medical/CRO/digital health companies. He previously held senior roles at Align Technology (Amsterdam), Boston Scientific (Paris), C.R. Bard (New Jersey), Sybron (Switzerland) and Becton Dickinson (UK) and was President of Gambro (Sweden) leading the £3bn public to private buyout. His industry experience covers pharma, biotech, digital, dental, devices and diagnostics.


  • Masters Marketing, University of the Arts, London
  • Bachelor Biology, Birmingham


In addition to the corporate work and Government advisory work, Mike is a frequent speaker at conferences and events. Topics include:

Digital Health in Mental Care

How can technology be used to bridge the gap between effective diagnosis and access to treatment. Will technology be able to address the current underspend on mental care, and will the ability to stay in e-contact be an improvement over sporadic face to face interventions.

Alzheimers the poor sister of Cancer

Why are there so few treatments for AD, why do so few products get from early wonder treatments to Phase III failure. Time to think beyond the randomised clinical study of the few and think how technology could enable digital monitoring at scale.

Why invest in UK Healthcare

Is the UK a good place for investors and those seeking investment. Does the liquidity of UK markets undervalue start-ups, is it inevitable that UK healthcare start-ups will migrate to the US or be sold before real value can be reached.

Can the UK learn from US Healthcare

How do we compare on key metrics and outcomes versus the US. Is the data on comparisons of the NHS v ROW a fair and unbiased account.

Innovation in Digital Healthcare

What will we be the impact of genomics, robotics, cell therapies, gene editing, on everyday care. Are we spending too much on bionic eyes for the few versus innovations that can deliver value for wider populations.

Who wants to Live forever

The challenge of living longer and how advances in medicine, materials and technology will make that happen, versus the need to live better. How effective are prevention campaigns and what is their long term value. Is the future NPV driven care?

How healthy is the UK Medtech investment space

A comparison of start-ups, flotations, exits and deals in the UK Medtech space. Should I place my bet here or in the USA? Where so few serial entrepreneurs in the UK, are we too frightened of failure to think big?

Independent Living and Technology

Will advances in medicine, materials and technology enable us to live more independently and keep us out of Hospitals. How will city design, transport and social changes enable a change in behaviours.

Innovation without Change Management is a Daydream

Is the lack of change management expertise the reason for the failure of too many mega-systems in the NHS. How do large corporates deliver change in comparison to public structures. Keep it simplesWhere is the place for AI in healthcare, is the real issue people or technology, and do we believe by bringing AI/ML into the mix, we will totally transform healthcare?


Mike will be starting teaching from September 2020.

Other activities

Mike is Chair of the Biocatalyst Major Awards (MAC2) Panel, Chairs the KTN MedTech Board, and the NIHR and SBRI and also acts as healthcare advisor for multiple private equity companies

He also works for Innovate UK with special interests in Robotics, AI, Medicines, Medical devices, Diagnostics, Dental, Digital Health, 5G, Adverse environments.